Home > Press > Evident Technologies Announces Issuance of Key Patent for Semiconductor Nanocrystals Made From III-V Materials
Abstract:
Evident Technologies, Inc. today announced the issuance of US Patent No. 7,399,429 covering the ability to make semiconductor nanocrystals from III-V materials, including indium galium phosphide. This newly issued patent represents a dramatic increase in the advancement of semiconductor materials science and augments the breadth of the company's intellectual property portfolio.
"The issuance of this key patent underscores the fact that Evident Technologies, Inc. remains a pioneer in the development of novel and proprietary semiconductor nanocrystals, and affords us broad protection in a rapidly growing segment of the market," stated Clint Ballinger Ph.D., CEO of Evident Technologies. "In response to a growing industry demand, our scientists have worked diligently over the past several years to develop new bright, stable III-V material systems."
Evident Technologies' broad array of semiconductor nanocrystal materials are already used in many industries around the world in products ranging from electronics to life science reagents. Companies and research institutes alike can benefit from this new, patented technology and continue the development of quantum dot applications from energy conversion to LEDs to life science.
"The unique spectral properties of these III-V quantum dot nanocrystals include absorption in the ultraviolet through the near-infrared range and emission in the near-infrared range, and are ideal for several applications within the life sciences," said Todd R. Nelson Ph.D., CEO of eBioscience, the worldwide, exclusive licensee of this technology within the life sciences industry. "We believe our customers will find that the products enabled by this technology will represent a significant advancement in multicolor applications, and will allow us to develop the next generation of eFluor in-vivo imaging reagents."
####
About Evident Technologies, Inc.
Founded in 2000, Evident Technologies develops and commercializes technology based on semiconductor nanocrystals. Evident is one of the first companies to commercialize products based on semiconductor nanotechnology and has launched commercial products in LED and lighting, military and life science markets.
About eBioscience Corporation
eBioscience provides innovative high quality reagents to academic and government researchers and pharmaceutical and biotech companies worldwide that empower the process of scientific discovery in the areas of cellular immunity and oncology. The company’s extensive portfolio of more than 8,000 leading edge cell analysis reagents and technologies, focused on flow cytometry and immunodetection, position our customers to be at the forefront of science. eBioscience is aligned with and responsive to the ever changing needs of its customers, making the company a preferred partner for scientific discovery.
Founded in 1999, eBioscience is headquartered in San Diego, California and conducts business in more than 70 countries around the world. For more information about eBioscience, visit the company's web site at www.eBioscience.com.
For more information, please click here
Contacts:
Schwartz Public Relations
Steven Wright-Mark
212-677-8700 ext. 29
Copyright © Business Wire 2008
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Chip Technology
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Groundbreaking precision in single-molecule optoelectronics August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||